STOCK TITAN

Aspen Group Reports 14% Revenue Growth for Third Quarter Fiscal 2022

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Negative)
Tags
Rhea-AI Summary

Aspen Group, Inc. (ASPU) reported a revenue increase to $18.9 million for Q3 FY 2022, up from $16.6 million in Q3 FY 2021, marking a 14% year-over-year growth. However, the company faced a net loss of ($3.7 million), wider than the ($2.8 million) loss in the previous year. The gross profit rose to $9.2 million with a 49% gross margin. A revised revenue outlook for FY 2022 is set at $75.5 million to $77.5 million, down from earlier guidance of $77.0 to $80.0 million. The company aims to meet robust demand in nursing education despite challenges posed by COVID-19.

Positive
  • Revenue increased to $18.9 million, 14% growth YoY.
  • Gross profit rose to $9.2 million.
  • New campus in Atlanta approved for BSN Pre-Licensure program.
Negative
  • Net loss of ($3.7 million), wider than ($2.8 million) YoY.
  • Revised revenue outlook lowered to $75.5-$77.5 million from $77.0-$80.0 million.
  • Gross margin decreased from 52% to 49% due to higher marketing costs.
  • Revenue increased to $18.9 million compared to $16.6 million last year
  • Business units with highest Lifetime Value (LTV) programs accounted for 56% of revenue
  • Net loss of ($3.7) million, including losses of $1.3 million related to new campus expansion
  • Received approval to open BSN Pre-Licensure program in Atlanta

NEW YORK, March 15, 2022 (GLOBE NEWSWIRE) -- Aspen Group, Inc. (Nasdaq: ASPU) (“AGI”), an education technology holding company, today announced financial results for its third quarter fiscal year 2022 ended January 31, 2022.

Third Quarter Fiscal Year 2022 Summary Results

 Three Months Ended January 31, Nine Months Ended January 31,
$ in millions, except per share data  2022   2021   2022   2021 
Revenue$18.9  $16.6  $57.3  $48.8 
Gross Profit1$9.2  $8.7  $29.3  $27.0 
Gross Margin (%)1 49%  52%  51%  55%
Net Income (Loss)$(3.7) $(2.8) $(7.5) $(8.1)
Earnings (Loss) per Share$(0.15) $(0.11) $(0.30) $(0.35)
EBITDA2$(2.4) $(2.2) $(4.2) $(4.5)
Adjusted EBITDA2$(1.3) $(0.9) $(1.5) $0.6 

_______________________                                                                                         
1 GAAP gross profit calculation includes marketing and promotional costs, instructional costs and services, and amortization expense of $0.4 million and $1.3 million, and $0.4 million and $1.0 million, for the three and nine months ended January 31, 2022 and 2021, respectively.
2 Non-GAAP financial measure. See reconciliations of GAAP to non-GAAP financial measures under "Non-GAAPFinancial Measures" starting on page 5.


“For the third quarter, Aspen Group delivered a 14% revenue increase year-over-year, despite the spike in Covid-19 infection rates driven by the Omicron variant, which caused critical healthcare staffing shortages and workload overloads for RNs during the quarter, lowering post-licensure degree program class starts amongst our predominantly RN student body,” said Michael Mathews, Chairman and CEO of AGI. “Importantly though, as the Omicron variant subsides, there are clear and prevailing longer-term trends in nursing that underpin robust demand for our offerings and reinforce our optimism for driving revenue growth and margin improvement. A growing number of nurses are leaving the profession as they reach retirement age or due to the pandemic-induced job fatigue. This supply-side trend, coupled with the rising demand for healthcare to support the aging U.S. population, is expected to perpetuate a nursing shortage through 2030. Registered nursing is one of the highest in-demand professions in the American workforce, and our EdTech platform puts us in a solid position to serve this growing market in an affordable way for students. Our recently improved balance sheet supports our long-term growth objectives.”

COVID-19 Update

Nursing students represented 87% of the Company’s total student body at the end of the third quarter of fiscal 2022. Of the 11,889 nursing students, 2,277 are BSN Pre-Licensure students located across our four metro locations (Phoenix, Austin, Tampa, and Nashville). The remaining 9,612 nursing students are licensed registered nurses (RNs) studying to earn an advanced degree (RN to BSN, MSN, MSN-FNP, or DNP degree programs). Post-licensure nursing students represent 70% of the Company’s total student body at the end of the third quarter and are the AGI students primarily affected by the COVID-19 pandemic.

Starting in the second half of June 2021 and continuing through January 2022, the Company saw lower course starts than seasonally expected among our RN student body. For example, at Aspen University, course starts among RNs from June 2021 through January 2022 increased by approximately 3% year-over-year. By comparison, over the previous two full fiscal years (Fiscal Year 2021 and Fiscal Year 2020), course starts among RNs at Aspen University increased by an average of approximately 10% year-over-year.

Aspen Group cannot be certain what impact future COVID-19 variants will have on the Company’s results through the remainder of Fiscal Year 2022 and into Fiscal Year 2023.

Liquidity

At January 31, 2022, the Company had cash and cash equivalents of $6.0 million, restricted cash of $1.4 million. Cash used in operations for the nine months ended January 31, 2022 was $7.7 million, which is attributed to changes in working capital to support increased revenue.

Earlier today, the Company announced financing agreements consisting of a $10 million convertible note and a $20 million revolving credit facility. Aspen Group received the proceeds of the convertible note at the closing. The $20 million revolving credit facility is undrawn. Additionally, the Company extended its existing $5 million Revolving Credit Facility by one year to November 4, 2023.

Updated Outlook for Fiscal Year 2022

The Company has revised its outlook for fiscal year 2022 revenue to a new range of $75.5 million to $77.5 million range from the prior range of $77.0 million to $80.0 million given in the second quarter fiscal 2022 earnings release on December 14, 2021.

The table below shows the revised forecast for fiscal year 2022 guidance metrics.

Dollar amounts in millions, except per share dataPrior Guidance Range Revised Guidance Range
Revenue$77.0  $80.0  $75.5  $77.5 
Net Income (Loss)$(9.0) $(7.0) $(11.5) $(10.5)
GAAP Earnings (Loss) per Share$(0.38) $(0.29) $(0.46) $(0.42)
EBITDA1$(5.0) $(3.0) $(7.5) $(6.5)
Adjusted EBITDA1$(2.0) $0.0  $(3.5) $(2.5)

1 See definitions of these Non-GAAP financial measures under "Non-GAAP–Financial Measures" starting on page 5. The guidance reconciliation follows a similar format.


Fiscal Q3 2022 Financial and Operational Results (compared to Fiscal Q3 2021)

Revenue increased to $18.9 million for Fiscal Q3 2022 compared to $16.6 million for Fiscal Q3 2021. Aspen University’s (AU) revenue in the third quarter of fiscal year 2022, which includes the high LTV BSN Pre-Licensure program, accounted for 69%, or $13.0 million, versus 71% or $11.9 million, of consolidated revenue in the prior year period. United States University (USU) revenue for the quarter, which includes the high LTV MSN-FNP program, accounted for 31%, or $5.9 million versus 29%, or $4.8 million of consolidated revenue in the prior year period.

GAAP gross profit increased 6% to $9.2 million for Fiscal Q3 2022 compared to $8.7 million for Fiscal Q3 2021. Gross margin was 49% for Fiscal Q3 2022 compared to 52% for Fiscal Q3 2021. Gross margin in Fiscal Q3 2022 was impacted by higher instructional and marketing costs related to the new locations within the BSN Pre-Licensure program. AU gross margin was 50% of AU revenue for Fiscal Q3 2022 versus 54% in Fiscal Q3 2021, and USU gross margin was 52% of USU revenue for Fiscal Q3 2022 versus 53% in Fiscal Q3 2021.

Net loss and net loss per share were ($3.7) million and ($0.15), respectively, for Fiscal Q3 2022 compared to ($2.8) million and ($0.11), respectively, for Fiscal Q3 2021. AU generated net income of $0.9 million for Fiscal Q3 2022 versus $1.4 million in Fiscal Q3 2021, and USU generated net income of $0.3 million for each Fiscal Q3 2022 and Fiscal Q3 2021. AGI corporate incurred a net loss of ($5.0) million for Fiscal Q3 2022 as compared to ($4.5) million in the prior year period.

EBITDA was ($2.4) million and (13%) margin, respectively, for Fiscal Q3 2022 compared to EBITDA of ($2.2) million and (13%) margin, respectively, for Fiscal Q3 2021.

For Fiscal Q3 2022, AU generated EBITDA of $1.9 million and 15% margin as compared to $1.9 million or 16% margin in Fiscal Q3 2021. USU generated EBITDA of $0.4 million and 7% margin, as compared to $0.4 million or 8% margin in Fiscal Q3 2021. AGI corporate incurred EBITDA of ($4.8) million as compared to ($4.5) million in Fiscal Q3 2021.

Adjusted EBITDA was ($1.3) million and (7%) margin, respectively, for Fiscal Q3 2022 compared to Adjusted EBITDA of ($0.9) million and (5%) margin, respectively, for Fiscal Q3 2021.

For Fiscal Q3 2022, AU generated Adjusted EBITDA of $2.2 million and 17% margin, as compared to $2.5 million, or 21% margin, in Fiscal Q3 2021. USU generated Adjusted EBITDA of $0.6 million and 10% margin, as compared to $0.5 million, or 10% margin, in Fiscal Q3 2021. AGI corporate incurred Adjusted EBITDA of ($4.1) million as compared to ($3.8) million in Fiscal Q3 2021.

Operating Metrics

New student enrollments for the past five quarters are shown below:

  New Student Quarterly Enrollments
  Q3'21 Q4'21 Q1'22 Q2'22 Q3'22
Aspen University 1,593  1,593  1,601  1,750  1,301 
USU 536  589  675  630  481 
Total 2,129  2,182  2,276  2,380  1,782 
                

New student enrollments, bookings and ARPU for Q3’22 compared to Q3’21 are shown below:

 Q3'21
Enrollments
 Q3'21
Bookings
1
 Q3'22
Enrollments
 Q3'22
Bookings
1
   (in millions)   (in millions)
Aspen University1,593  $23.5  1,301  $17.8 
USU536  $9.6  481  $8.6 
Total2,129  $33.0  1,782  $26.3 
ARPU  $15,513    $14,785 

_____________________
1 “Bookings” are defined by multiplying Lifetime Value (LTV) by new student enrollments for each operating unit. “Average Revenue Per Enrollment” (ARPU) is defined by dividing total Bookings by total new student enrollments for each operating unit.


New student enrollments at AU decreased year-over-year by 18% due to the planned reduction of BSN Pre-Licensure enrollments in the Phoenix metro and the impact of COVID-19, specifically the effect that the Omicron variant surge has had among prospective RN students beginning in November 2021. New student enrollments at USU decreased by 10% year-over-year. RN student enrollments at USU were similarly impacted by COVID-19.

To provide context, the third quarter enrollment decrease of 16% year-over-year on a Company-wide basis was primarily a result of three factors:

  • First, as previously disclosed, Aspen University reduced advertising spend in the Phoenix metro for the BSN pre-licensure program to a maintenance spend level through January, causing enrollments in that metro to drop by 51% year-over-year. The quarter was not affected by the temporary suspension of advertising and enrollments of new pre-licensure students in the Phoenix metro, which happened after the quarter closed.
  • Second, enrollments at USU were down 10% year-over-year given the impact of the ongoing COVID-19 pandemic, as prospective post-licensure nursing students continue to delay their education goals on a short-term basis as they cared for COVID patients.
  • Third, in addition to Aspen University also seeing a COVID effect among prospective nursing post-licensure students, Aspen’s 2.0 business plan called for a $1.3 million annual reduction of ad spend in fiscal 2022 in Aspen’s post-licensure Nursing + Other unit. In the third quarter this equated to a 14% drop in ad spend year-over-year. Consequently, given the drop in ad spend and the COVID effect, enrollments in the Aspen Nursing + Other unit dropped by 18% year-over-year.

In summary, excluding the 51% drop in enrollments in the Phoenix metro (BSN pre-licensure program) and the 18% drop in enrollments in Aspen University's Nursing + Other unit, total enrollments for the Company would have been down by approximately 1% year-over-year.

The chart below shows five quarters of active student body results. Active student body is comprised of active degree-seeking students, enrolled in a course at the end of the third quarter of fiscal year 2022 or are registered for an upcoming course.

A graph accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/9a608899-b65c-467c-9630-668840facf4c

AGI’s overall active degree-seeking student body (includes both Aspen University and USU) grew 2% year-over-year to 13,724 as of January 31, 2022 from 13,407 as of January 31, 2021 and students seeking nursing degrees were 11,889 or 87% of total active students at both universities. Of the 11,889 students seeking nursing degrees, 9,612 are RNs studying to earn an advanced degree, including 6,839 at Aspen University and 2,773 at USU, while the remaining 2,277 nursing students are enrolled in Aspen University’s BSN Pre-Licensure program in the Phoenix, Austin, Tampa, Nashville and Atlanta metros.

Conference Call

Aspen Group, Inc. will host a conference call to discuss its third quarter fiscal year 2022 results and business outlook on Tuesday, March 15, 2022, at 4:30 pm ET. Aspen Group, Inc. will issue a press release reporting results after the market closes on that day. The conference call can be accessed by dialing toll-free (844) 452-6823 (U.S.) or (731) 256-5216 (International), passcode 9807158.

Subsequent to the call, a transcript of the audio cast will be available from the Company’s website at www.aspu.com. There will also be a seven day dial-in replay which can be accessed by dialing toll-free (855) 859-2056 (U.S.) or (404) 537-3406 (International), passcode 9807158.

For additional information on the financial statements and performance, please refer to the Aspen Group, Inc. Form 10-Q for the third quarter of fiscal year 2022 and third quarter 2022 Financial Results Presentation published on the Company’s website at www.aspu.com, on the Presentations page under Company Info.

Non-GAAP – Financial Measures

This press release includes both financial measures in accordance with Generally Accepted Accounting Principles, or GAAP, as well as non-GAAP financial measures. Generally, a non-GAAP financial measure is a numerical measure of a company’s performance, financial position or cash flows that either excludes or includes amounts that are not normally included or excluded in the most directly comparable measure calculated and presented in accordance with GAAP. Non-GAAP financial measures should be viewed as supplemental to, and should not be considered as alternatives to net income (loss), operating income (loss), and cash flow from operating activities, liquidity or any other financial measures. They may not be indicative of the historical operating results of AGI nor are they intended to be predictive of potential future results. Investors should not consider non-GAAP financial measures in isolation or as substitutes for performance measures calculated in accordance with GAAP.

Our management uses and relies on EBITDA, Adjusted EBITDA and Adjusted EBITDA Margin, which are non-GAAP financial measures. We believe that management, analysts, and shareholders benefit from referring to the following non-GAAP financial measures to evaluate and assess our core operating results from period-to-period after removing the impact of items that affect comparability. Our management recognizes that the non-GAAP financial measures have inherent limitations because of the excluded items described below.

We have included a reconciliation of our non-GAAP financial measures to the most comparable financial measures calculated in accordance with GAAP. We believe that providing the non-GAAP financial measures, together with the reconciliation to GAAP, helps investors make comparisons between AGI and other companies. In making any comparisons to other companies, investors need to be aware that companies use different non-GAAP measures to evaluate their financial performance. Investors should pay close attention to the specific definition being used and to the reconciliation between such measure and the corresponding GAAP measure provided by each company under applicable SEC rules.

AGI defines Adjusted EBITDA as EBITDA excluding: (1) bad debt expense; (2) stock-based compensation; and (3) non-recurring charges. The following table presents a reconciliation of net loss to EBITDA and Adjusted EBITDA and of net income (loss) margin to the Adjusted EBITDA margin:

 Three Months Ended January 31, Nine Months Ended January 31,
  2022   2021   2022   2021 
Net loss$(3,733,997) $(2,815,266) $(7,457,143) $(8,128,987)
Interest expense, net 180,642   33,436   350,838   2,018,176 
Taxes 231,610   10,460   388,520   45,090 
Depreciation and amortization 883,536   535,273   2,480,179   1,552,254 
EBITDA (2,438,209)  (2,236,097)  (4,237,606)  (4,513,467)
Bad debt expense 350,000   670,000   1,050,000   1,702,000 
Stock-based compensation 700,697   701,170   1,965,567   3,019,828 
Non-recurring charges - Severance       19,665   44,000 
Non-recurring (income) charges - Other 49,310      (345,056)  375,437 
Adjusted EBITDA$(1,338,202) $(864,927) $(1,547,430) $627,798 
Net loss Margin (20)%   (17)%   (13)%   (17)% 
Adjusted EBITDA Margin (7)%   (5)%   (3)%   1% 
                

The following tables present a reconciliation of net loss to EBITDA and Adjusted EBITDA and of net income (loss) margin to the Adjusted EBITDA margin by business unit:

 Three Months Ended January 31, 2022
 Consolidated AGI Corporate AU USU
Net income (loss)$(3,733,997) $(5,020,149) $941,437  $344,715 
Interest expense, net 180,642   180,682      (40)
Taxes 231,610   951   230,660   (1)
Depreciation and amortization 883,536   47,536   738,172   97,828 
EBITDA (2,438,209)  (4,790,980)  1,910,269   442,502 
Bad debt expense 350,000      225,000   125,000 
Stock-based compensation 700,697   616,166   56,880   27,651 
Non-recurring charges - Severance           
Non-recurring charges - Other 49,310   49,310       
Adjusted EBITDA$(1,338,202) $(4,125,504) $2,192,149  $595,153 
Net income (loss) Margin (20)%  NM  7%   6% 
Adjusted EBITDA Margin (7)%  NM  17%   10% 

________________________________
NM - Not meaningful

 Three Months Ended January 31, 2021
 Consolidated AGI Corporate AU USU
Net income (loss)$(2,815,266) $(4,537,882) $1,375,359  $347,257 
Interest expense, net 33,436   33,516      (80)
Taxes 10,460   3,600   6,800   60 
Depreciation and amortization 535,273   15,540   492,303   27,430 
EBITDA (2,236,097)  (4,485,226)  1,874,462   374,667 
Bad debt expense 670,000      610,000   60,000 
Stock-based compensation 701,170   692,244   (12,468)  21,394 
Non-recurring charges - Severance           
Non-recurring charges - Other           
Adjusted EBITDA$(864,927) $(3,792,982) $2,471,994  $456,061 
Net income (loss) Margin (17)%  NM  12%   7% 
Adjusted EBITDA Margin (5)%  NM  21%   10% 


 Nine Months Ended January 31, 2022
 Consolidated AGI Corporate AU USU
Net income (loss)$(7,457,143) $(14,537,849) $4,605,707  $2,474,999 
Interest expense, net 350,838   353,193   (1,739)  (616)
Taxes 388,520   3,363   383,867   1,290 
Depreciation and amortization 2,480,179   116,720   2,082,972   280,487 
EBITDA (4,237,606)  (14,064,573)  7,070,807   2,756,160 
Bad debt expense 1,050,000      725,000   325,000 
Stock-based compensation 1,965,567   1,732,412   149,773   83,382 
Non-recurring charges - Severance 19,665         19,665 
Non-recurring (income) charges - Other (345,056)  107,635   (452,691)   
Adjusted EBITDA$(1,547,430) $(12,224,526) $7,492,889  $3,184,207 
Net income (loss) Margin (13)%  NM  12%   14% 
Adjusted EBITDA Margin (3)%  NM  19%   17% 


 Nine Months Ended January 31, 2021
 Consolidated AGI Corporate AU USU
Net income (loss)$(8,128,987) $(15,929,868) $5,892,892  $1,907,989 
Interest expense, net 2,018,176   2,018,258      (82)
Taxes 45,090   14,250   30,580   260 
Depreciation and amortization 1,552,254   42,023   1,424,030   86,201 
EBITDA (4,513,467)  (13,855,337)  7,347,502   1,994,368 
Bad debt expense 1,702,000      1,522,000   180,000 
Stock-based compensation 3,019,828   2,768,687   135,166   115,975 
Non-recurring charges - Severance 44,000   44,000       
Non-recurring charges - Other 375,437   375,437       
Adjusted EBITDA$627,798  $(10,667,213) $9,004,668  $2,290,343 
Net income (loss) Margin (17)%  NM  17%   14% 
Adjusted EBITDA Margin 1%  NM  26%   16% 
              

Definitions

Lifetime Value ("LTV") – is calculated as the weighted average total amount of tuition and fees paid by every new student that enrolls in the Company’s universities, after giving effect to attrition.

Bookings – is defined by multiplying LTV by new student enrollments for each operating unit.

Average Revenue per Enrollment ("ARPU") – is defined by dividing total bookings by total enrollments.

Adjusted EBITDA Margin – is defined as Adjusted EBITDA divided by revenue. We believe Adjusted EBITDA margin is useful for management, analysts and investors as this measure allows for a more meaningful comparison between our performance and that of our competitors. Adjusted EBITDA margin has certain limitations in that it does not take into account the impact to our consolidated statement of operations of certain expenses.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 including the nursing shortage, our 2022 guidance, our liquidity, the impact of COVID-19 on our business including our RN to BSN program and our estimates as to Lifetime Value, bookings and ARPU. The words “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Important factors that could cause actual results to differ from those in the forward-looking statements include the continued demand of nursing students for the new programs, student attrition, national and local economic factors including whether COVID-19 will continue to have an adverse effect on the economy, uncertainties arising from the Russian invasion of Ukraine including its effect on the U.S. economy, supply chain issues and the labor market, competition from nursing schools in local markets, the competitive impact from the trend of non-profit universities using online education and consolidation among our competitors, and the impact of possible actions arising from the Arizona Board of Nursing investigation. Other risks are included in our filings with the SEC including our Form 10-K for the year ended April 30, 2021, as amended by the Form 10-Q for the fiscal quarter ended January 31, 2022. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

About Aspen Group, Inc.

Aspen Group, Inc. is an education technology holding company that leverages its infrastructure and expertise to allow its two universities, Aspen University and United States University, to deliver on the vision of making college affordable again.

Investor Relations Contact

Kim Rogers
Managing Director
Hayden IR
385-831-7337 
Kim@HaydenIR.com


GAAP Financial Statements

ASPEN GROUP, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS

  January 31, 2022 April 30, 2021
  (Unaudited)  
Assets    
Current assets:    
Cash and cash equivalents $5,969,286  $12,472,082 
Restricted cash  1,433,397   1,193,997 
Accounts receivable, net of allowance of $3,381,204 and $3,289,816, respectively  19,635,715   16,724,744 
Prepaid expenses  1,375,628   1,077,831 
Other current assets  31,032   68,529 
Total current assets  28,445,058   31,537,183 
     
Property and equipment:    
Computer equipment and hardware  1,486,201   956,463 
Furniture and fixtures  2,153,124   1,705,101 
Leasehold improvements  7,179,896   5,729,324 
Instructional equipment  656,409   421,039 
Software  9,829,329   8,488,635 
Construction in progress  900   247,767 
   21,305,859   17,548,329 
Less: accumulated depreciation and amortization  (7,533,571)  (4,892,987)
Total property and equipment, net  13,772,288   12,655,342 
Goodwill  5,011,432   5,011,432 
Intangible assets, net  7,907,075   7,908,360 
Courseware, net  289,680   187,296 
Accounts receivable, net of allowance of $— and $625,963, respectively     45,329 
Long-term contractual accounts receivable  12,701,452   10,249,833 
Deferred financing costs  88,393   18,056 
Operating lease right of use assets, net  13,090,470   12,714,863 
Deposits and other assets  523,898   479,212 
Total assets $81,829,746  $80,806,906 

(Continued)

ASPEN GROUP, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS (CONTINUED)

  January 31, 2022 April 30, 2021
  (Unaudited)  
Liabilities and Stockholders’ Equity    
Liabilities:    
Current liabilities:    
Accounts payable $1,806,656  $1,466,488 
Accrued expenses  2,079,249   2,040,896 
Deferred revenue  6,182,781   6,825,014 
Due to students  3,229,516   2,747,484 
Operating lease obligations, current portion  2,106,981   2,029,821 
Credit Facility  5,000,000    
Other current liabilities  136,027   307,921 
Total current liabilities  20,541,210   15,417,624 
     
Operating lease obligations, less current portion  17,317,396   16,298,808 
Total liabilities  37,858,606   31,716,432 
     
Commitments and contingencies    
     
Stockholders’ equity:    
Preferred stock, $0.001 par value; 1,000,000 shares authorized,    
0 issued and 0 outstanding at January 31, 2022 and April 30, 2021      
Common stock, $0.001 par value; 40,000,000 shares authorized,    
25,228,580 issued and 25,073,094 outstanding at January 31, 2022    
25,066,297 issued and 24,910,811 outstanding at April 30, 2021  25,229   25,067 
Additional paid-in capital  111,378,471   109,040,824 
Treasury stock (155,486 at both January 31, 2022 and April 30, 2021)  (1,817,414)  (1,817,414)
Accumulated deficit  (65,615,146)  (58,158,003)
Total stockholders’ equity  43,971,140   49,090,474 
Total liabilities and stockholders’ equity $81,829,746  $80,806,906 
         


ASPEN GROUP, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)

  Three Months Ended January 31, Nine Months Ended January 31,
   2022   2021   2022   2021 
Revenue $18,944,798  $16,624,837  $57,316,004  $48,761,444 
         
Operating expenses:        
Cost of revenue (exclusive of depreciation and amortization shown separately below)  9,275,419   7,559,951   26,658,188   20,732,254 
General and administrative  11,771,487   10,644,438   34,359,276   30,723,349 
Bad debt expense  350,000   670,000   1,050,000   1,702,000 
Depreciation and amortization  883,536   535,273   2,480,179   1,552,254 
Total operating expenses  22,280,442   19,409,662   64,547,643   54,709,857 
         
Operating loss  (3,335,644)  (2,784,825)  (7,231,639)  (5,948,413)
         
Other income (expense):        
Interest expense  (180,697)  (33,539)  (353,738)  (2,018,664)
Other income (expense), net  13,954   13,558   516,754   (116,820)
Total other (expense) income, net  (166,743)  (19,981)  163,016   (2,135,484)
         
Loss before income taxes  (3,502,387)  (2,804,806)  (7,068,623)  (8,083,897)
         
Income tax expense  231,610   10,460   388,520   45,090 
         
Net loss $(3,733,997) $(2,815,266) $(7,457,143) $(8,128,987)
         
Net loss per share - basic and diluted $(0.15) $(0.11) $(0.30) $(0.35)
         
Weighted average number of common stock outstanding - basic and diluted  25,041,733   24,544,334   24,971,056   23,354,036 
                 


ASPEN GROUP, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY
Three Months Ended January 31, 2022 and 2021
(Unaudited)

  Common Stock Additional
Paid-In
Capital
 Treasury
Stock
 Accumulated
Deficit
 Total
Stockholders’
Equity
  Shares Amount    
Balance at October 31, 2021 25,148,194 $25,149 $110,526,729  $(1,817,414) $(61,881,149) $46,853,315 
Stock-based compensation     700,697         700,697 
Common stock issued for stock options exercised for cash 41,667  41  134,959         135,000 
Common stock issued for vested restricted stock units 38,719  39  (39)         
Amortization of warrant based cost     16,125         16,125 
Net loss           (3,733,997)  (3,733,997)
Balance at January 31, 2022 25,228,580 $25,229 $111,378,471  $(1,817,414) $(65,615,146) $43,971,140 
             
             
  Common Stock Additional
Paid-In
Capital
 Treasury
Stock
 Accumulated
Deficit
 Total
Stockholders’
Equity
  Shares Amount    
Balance at October 31, 2020 24,416,539 $24,417 $105,092,551  $  $(53,022,751) $52,094,217 
Stock-based compensation     701,170         701,170 
Common stock issued for stock options exercised for cash 447,134  447  2,180,352   (1,817,414)     363,385 
Common stock issued for vested restricted stock units 74,000  74  (74)         
Common stock issued for services 2,000  2  19,898         19,900 
Amortization of warrant based cost     9,125         9,125 
Net loss           (2,815,266)  (2,815,266)
Balance at January 31, 2021 24,939,673 $24,940 $108,003,022  $(1,817,414) $(55,838,017) $50,372,531 
                      


ASPEN GROUP, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY (CONTINUED)
Nine Months Ended January 31, 2022 and 2021
(Unaudited)

  Common Stock Additional
Paid-In
Capital
 Treasury
Stock
 Accumulated
Deficit
 Total
Stockholders’
Equity
  Shares Amount    
Balance at April 30, 2021 25,066,297 $25,067 $109,040,824  $(1,817,414) $(58,158,003) $49,090,474 
Stock-based compensation     1,965,567         1,965,567 
Common stock issued for stock options exercised for cash 58,419  58  190,976         191,034 
Common stock issued for cashless stock options exercised 30,156  30  (30)         
Common stock issued for vested restricted stock units 73,708  74  (74)         
Amortization of warrant based cost     43,708         43,708 
Warrants issued for deferred financing costs related to Credit Facility     137,500         137,500 
Net loss           (7,457,143)  (7,457,143)
Balance at January 31, 2022 25,228,580 $25,229 $111,378,471  $(1,817,414) $(65,615,146) $43,971,140 
             
             
             
             
  Common Stock Additional
Paid-In
Capital
 Treasury
Stock
 Accumulated
Deficit
 Total
Stockholders’
Equity
  Shares Amount    
Balance at April 30, 2020 21,770,520 $21,771 $89,505,216  $(70,000) $(47,709,030) $41,747,957 
Stock-based compensation     3,019,828         3,019,828 
Common stock issued for stock options exercised for cash 1,364,721  1,365  4,394,749   (1,817,414)     2,578,700 
Common stock issued for cashless stock options exercised 22,339  22  (22)         
Common stock issued for conversion of Convertible Notes 1,398,602  1,399  9,998,601         10,000,000 
Common stock issued for vested restricted stock units 206,109  206  (206)         
Common stock issued for warrants exercised for cash 192,049  192  1,081,600         1,081,792 
Common stock issued for services 2,000  2  19,898         19,900 
Modification charge for warrants exercised     25,966         25,966 
Amortization of warrant based cost     27,375         27,375 
Cancellation of Treasury Stock (16,667  (17  (69,983)  70,000       
Net loss           (8,128,987)  (8,128,987)
Balance at January 31, 2021 24,939,673 $24,940 $108,003,022  $(1,817,414) $(55,838,017) $50,372,531 
                      


ASPEN GROUP, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)

  Nine Months Ended January 31,
   2022   2021 
Cash flows from operating activities:    
Net loss $(7,457,143) $(8,128,987)
Adjustments to reconcile net loss to net cash used in operating activities:    
Bad debt expense  1,050,000   1,702,000 
Depreciation and amortization  2,480,179   1,552,254 
Stock-based compensation  1,965,567   3,019,828 
Amortization of warrant based cost  43,708   27,375 
Amortization of debt discounts     1,550,854 
Amortization of debt issue costs  18,056   156,029 
Amortization of deferred financing costs  49,107    
Modification charge for warrants exercised     25,966 
Loss on asset disposition  36,445    
Lease benefit  (96,450)   
Tenant improvement allowances received from landlords  816,591    
Common stock issued for services     19,900 
Changes in operating assets and liabilities:    
Accounts receivable  (6,412,590)  (6,493,238)
Prepaid expenses  (297,797)  (267,526)
Other receivables     23,097 
Other current assets  37,498   (1,205,083)
Accounts receivable, other  45,329    
Deposits and other assets  (44,686)  (185,599)
Accounts payable  340,168   (349,882)
Accrued expenses  38,353   1,756,102 
Due to students  482,032   (128,154)
Deferred revenue  (642,233)  1,887,377 
Other current liabilities  (171,894)  (238,032)
Net cash used in operating activities  (7,719,760)  (5,275,719)
Cash flows from investing activities:    
Purchases of courseware and accreditation  (161,262)  (31,330)
Purchases of property and equipment  (3,573,408)  (2,877,758)
Net cash used in investing activities  (3,734,670)  (2,909,088)
Cash flows from financing activities:    
Borrowings under the Credit Facility  5,000,000    
Proceeds from stock options exercised  191,034   2,578,700 
Proceeds from warrants exercised     1,081,792 
Net cash provided by financing activities  5,191,034   3,660,492 

(Continued)

ASPEN GROUP, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS (CONTINUED)
(Unaudited)

  Nine Months Ended January 31,
   2022   2021 
Net decrease in cash, cash equivalents and restricted cash $(6,263,396) $(4,524,315)
Cash, cash equivalents and restricted cash at beginning of period  13,666,079   17,906,765 
Cash, cash equivalents and restricted cash at end of period $7,402,683  $13,382,450 
     
Supplemental disclosure cash flow information:    
Cash paid for interest $258,630  $310,958 
Cash paid for income taxes $13,520  $49,008 
     
Supplemental disclosure of non-cash investing and financing activities:    
Common stock issued for conversion of Convertible Notes $  $10,000,000 
Warrants issued as part of Credit Facility $137,500  $ 
         

The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the accompanying consolidated balance sheet to the total amounts shown in the accompanying unaudited consolidated statements of cash flows:

  January 31, 2022 April 30, 2021
Cash and cash equivalents $5,969,286  $12,472,082 
Restricted cash  1,433,397   1,193,997 
Total cash, cash equivalents and restricted cash $7,402,683  $13,666,079 

 


FAQ

What was Aspen Group's revenue for Q3 FY 2022?

Aspen Group reported a revenue of $18.9 million for Q3 FY 2022.

What is the revised revenue outlook for Aspen Group in FY 2022?

The revised revenue outlook for FY 2022 is between $75.5 million and $77.5 million.

How much was the net loss reported by Aspen Group for Q3 FY 2022?

Aspen Group reported a net loss of $3.7 million for Q3 FY 2022.

What percentage of revenue did the BSN Pre-Licensure program contribute?

Business units with the highest Lifetime Value programs contributed 56% of revenue.

ASPEN GROUP INC

OTC:ASPU

ASPU Rankings

ASPU Latest News

ASPU Stock Data

814.18k
25.70M
7.65%
10.56%
0.23%
Education & Training Services
Consumer Defensive
Link
United States of America
New York